---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-291671"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:38:40.193825+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics receives Nasdaq bid price deficiency notice; has until June 3, 2024 to regain compliance

## Summary
- Received Nasdaq notice on Dec 4, 2023 for failing minimum bid price of $1.00 for 30 consecutive trading days.
- Has 180 calendar days, until June 3, 2024, to regain compliance by closing bid >=$1.00 for 10 consecutive days.
- If not compliant by June 3, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
- No immediate effect on listing; company intends to monitor and consider options to cure deficiency.

## SEC filing metadata
- accession: 0001193125-23-291671
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523291671/0001193125-23-291671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523291671/d565852d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-291671
- JSON: https://secwatch.observer/filing/0001193125-23-291671.json
- Plain text: https://secwatch.observer/filing/0001193125-23-291671.txt

## Key facts
- Listing & Compliance Notices
  Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: December 4, 2023, Quince Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523291671/0001193125-23-291671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.